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ABSTRACT 
 
OBJECTIVE- Bartter’s syndrome is a rare genetic disorder characterized by renal  
salt wasting, hypokalemia and metabolic alkalosis. CASE REPORT: A 32 years 
old male patient presented to casualty with complaints of generalised 
weakness and chest pain of 15 days duration. Patient had pallor, with loss of 
buccal pad of fat, skin turgor was lost, and extremities were cold. PR-90bpm, 
feeble, BP-50/40mmHg. History of similar complaints 1 month back for which 
he was hospitalised for 15 days and was not completely relieved of symptoms. 
The differential diagnosis of metabolic alkalosis with hypokalemia without 
hypertension are; 1. Bartter’s syndrome, 2. Gitelman’s syndrome, 3. 
Surreptitious vomiting and 4. Diuretic abuse. CONCLUSION: Acquired Bartter’s 
and Gitelman’s l ike syndromes have been described with autoimmune 
disorders, sarcoidosis and various drugs. This patient could have a yet 
undetected or unknown mutation of a protein which has a structural or a 
functional role in renal tubular cells (of Loop of Henle).  
KEY WORDS: bartter’s  syndrome, renal salt wasting, hypokalemia, metabolic 
alkalosis, sarcoidosis. 
INTRODUCTION 
Bartter’s syndrome is a rare genetic disorder1, where in there 
are specific defects in the channels governing the normal 
functioning of kidney, leading to abnormal loss of electrolytes 
including sodium, potassium, chloride and calcium etc. 
Bartter’s syndrome is characterised by renal salt wasting, 
hypokalaemia and metabolic alkalosis [1]. Bartter’s  s yndrome 
is classified into 5 types based on the channel involved due to 
specific mutation in the genes coding for that specific 
channel. BS type 1 is l inked to mutations of the gene SLC12A1 
(Solute carrier family 12 sodium/potassium/chloride 
transporters, member 1) on chromosome 15 (15q15-q21.1). 
BS type 2 is l inked to a gene called KCNJ1 (mapped to 
chromosome 11q21-25), BS type 3 is l inked to the gene 
ClCNKb (mapped to chromosome 1p36) while BS type 4 is 
l inked to gene BSND (mapped to chromosome 1p31). BS type 
5 is associated with activating mutations of the CASR gene 
(mapped to chromosome 3q13.3-q21)[1].  
CASE REPORT 
A 32 years old male patient presented to casualty with 
complaints of generalised weakness and chest pain of 15 
days duration. The chest pain was diffuse dull aching type, 
non radiating, not associated with vomiting or syncope. 
Patient had history of similar complaints 1 month back for 
which he was hospitalised for 15 days in other hospital and 
was not completely relieved of symptoms.  All  other family 
members are keeping good health. Patient gives history of 
consumption of alcohol for 10 years, 1-2 quarters per day. On 
examination patient had pallor, with loss of buccal pad of fa t, 
skin turgor was lost, and extremities were cold. PR-90 bpm, 
feeble, BP-50/40 mmHg. Patient was conscious and well 
oriented. Patient had hepatomegaly and periumbilical 
tenderness on deep palpation. 
Treatment was started with IV Fluids of 3L on day one 
following which BP was 64/48 mmHg, and later Dopamine 
infusion was started @ 3ml/hr for two days following which 
dose was tapered and stopped with BP of 118/70 mmHg.  
Complete blood count and renal profile was done depicted i n 
table one, revealing hypokalaemia and hyponatraemia with 
raised creatinine and urea on day one,  as severe 
hypokalaemia (K+ 2.0) was present on day 1  correction was 
started with an infusion of 1 ampule  of KCl in 100ml NS over 
4 hours, following which potassium levels was 2.6 mg/dl on 
day two and potassium  was continued with oral KCl 
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supplements of 15 ml thrice a day  and potassium rich diet, 
even then potassium was on lower side on day three i.e, 
2.6mg/dl .  
Table 1 also reveals hypocalcaemia and normal magnesium, 
to evaluate for the persistence of hypokalemia urinary 
osmolality (273 mosm/kg), urinary sodium (46 mmol/24hrs) 
and urinary potassium (20.4 mmol/24hrs) were done and 
depicted in table one.  
Table 1. Blood investigations on Day 1, Day 2, and Day 3. 
 
A clinical approach to know the cause of hypokalaemia  was 
done. 
The Trans Tubular Potassium Gradient (TTKG) here is 9.8 and 
ABG analysis shows metabolic alkalosis and USG abdomen 
shows normal kidney size and shape with peritoneal cavity 
showing accumulation of fluid. 
DISCUSSION 
On evaluating for persistence of low potassium levels even 
with intravenous and oral potassium correction, our patient 
had increased loss of urinary potassium 20.4 mmol/day i.e, 
>15 mmol/day and TTKG > 9.8 indicating that the loss is 
through renal tubules and ABG analysis showing metabolic 
alkalosis. The differential diagnosis constituting these 
parameters includes -  1. Surreptitious vomiting, 2. Diuretic 
abuse, 3. Bartter’s syndrome and 4. Gitelman’s syndrome. 
The first two are ruled out as no history suggestive of the 
same, Gitelman’s syndrome can be ruled out based on 
magnesium levels which are within normal levels and are not 
low as in Gitelman’s syndrome[2], hence Barter’s syndrome is 
the probable diagnosis.  
 
 
 
 
 
 
 
Acquired Bartter’s syndrome and Gitelman’s l ike syndrome 
are associated with autoimmune disorders l ike sarcoidosis 
and various drugs [3, 4]. 
CONCLUSION  
We speculate that this patient represents Bartter’s 
syndrome, and the same should be considered as a 
provisional diagnosis in patients with electrolyte disturbances 
as mentioned above irrespective of clinical presentation and 
age of presentation, Bartter’s syndrome is also documented 
in elderly too[5]. 
This patient may have a new acquired mutation in renal 
tubular cells, and this mutation couldn’t be confirmed in our 
patient as the genetic testing for Bartter’s syndrome is not 
available in India
[6]. 
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DAY OF ADMISSION  DAY 1 DAY 2 
TOTAL COUNT 16700 cells/cumm   
RBC 3.54 millions/cumm   
HEMOGLOBIN  9.4 gm%   
PLATELET COUNT  3.19Lkh   
ESR 70mm at 1st hour   
RBS  80mg/dl   
CREATININE 3.5 mg/dl   
S. MAGNESIUM 1.6 mg/dl   
S. SODIUM 121 mg/dl    130 mg/dl 126 mg/dl 
S. POTASSIUM 2.0 mg/dl 2.6 mg/dl 2.6 mg/dl 
U. OSMOLALITY 273.0 mOsm/kg   
U. SODIUM 46.0 mmol/day   
U. POTASSIUM 20.4mmol/day   
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